MLL
BIOC

Moody Lynn & Lieberson’s Biocept, Inc. BIOC Stock Holding History

Moody Lynn & Lieberson’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1
Closed -$38K – 202
2015
Q2 		$38K Buy
+1
New +$76.8K 0.01% 188

Other funds holding BIOC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Moody Lynn & Lieberson's BIOC Position: Q3 2015 in Review

Moody Lynn & Lieberson sold out of Biocept, Inc. (BIOC) in Q3 2015, closing a stake of 1 share — an estimated $38K sold.

Moody Lynn & Lieberson first reported a position in BIOC in Q2 2015 and held it in 1 quarter. The position peaked at $38K in Q2 2015. 17 funds tracked by Wall St. Rank hold BIOC as of Q3 2015.

  • Moody Lynn & Lieberson reported no remaining Biocept, Inc. position as of Q3 2015 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 1 Biocept, Inc. share in Q3 2015, an estimated $38K.
  • Moody Lynn & Lieberson first reported a position in Biocept, Inc. in Q2 2015 and held it in 1 quarter.
  • Moody Lynn & Lieberson's Biocept, Inc. position peaked at $38K in Q2 2015.
  • 17 funds tracked by Wall St. Rank held Biocept, Inc. as of Q3 2015.

Based on Moody Lynn & Lieberson's 13F filing for Q3 2015, filed 28 Oct 2015.